Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not respond to treatment (refractory) or stage III-IV non-small cell lung cancer. Personalized neo-antigen peptide vaccine is a product that combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Stan ogólny pacjenta pozwala na leczenie (skala ECOG 0, 1 lub 2).
- •Istnienie co najmniej jednej zmiany nowotworowej o odpowiednich wymiarach lub możliwość pobrania próbki tkanki do analizy.
- •Choroba jest widoczna w badaniach obrazowych i nadaje się do pomiaru (zgodnie z kryteriami RECIST 1.1).
- •Prawidłowe wyniki badań krwi wskazujące na dobrą pracę nerek i wątroby.
- •Niewielkie problemy z oddychaniem lub prawidłowe nasycenie krwi tlenem.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
FHCC Intake
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.